Promising biomarkers and therapeutic targets for the management of Parkinson's disease: recent advancements and contemporary research

Parkinson's disease (PD) is one of the progressive neurological diseases which affect around 10 million population worldwide. The clinical manifestation of motor symptoms in PD patients appears later when most dopaminergic neurons have degenerated. Thus, for better management of PD, the development of accurate biomarkers for the early prognosis of PD is imperative. The present work will discuss the potential biomarkers from various attributes covering biochemical, microRNA, and neuroimaging aspects (alpha-synuclein, DJ-1, UCH-L1, beta-glucocerebrosidase, BDNF, etc.) for diagnosis, recent development in PD management, and major limitations with current and conventional anti-Parkinson therapy. This manuscript summarizes potential biomarkers and therapeutic targets, based on available preclinical and clinical evidence, for better management of PD.

Automated summary

Parkinson's disease (PD) is a progressive neurological disease that affects approximately 10 million people worldwide. The manifestation of motor symptoms in PD patients occurs later, after the degeneration of most dopaminergic neurons. Therefore, the development of accurate biomarkers for early prognosis of PD is crucial for better management. This manuscript discusses potential biomarkers from various aspects, including biochemical, microRNA, and neuroimaging, for diagnosis, recent developments in PD management, and limitations of current anti-Parkinson therapy.